

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PATENT ABSTRACTS OF JAPAN

(11)Publication **64-025800**
n number :

(43)Date of **27.01.1989**
publication of
application :

(51)Int.Cl.

C07K 15/12

A61K 39/29

C07K 7/08

C07K 7/10

C07K 13/00

// C12P 21/00

C07K 99:00

(21)Applicati **62-311803**
on number :

(22)Date of **09.12.1987**
filing :

(71)Applicant **SCRIPPS CLINIC RES FOUND**
:

(72)Inventor : **THORNTON GEORGE B**
MORIARTY ANN M
MILICH DAVID R
MCLACHLAN ALAN

(30)Priority

Priority number :	86 939617	Priority date :	09.12.1986	Priority country :	US
	87 106538		07.10.1987		US

(54) THE CELL EPITOPE OF HEPATITIS B VIRUS NUCLEOCAPSID PROTEIN

(57)Abstract:

NEW MATERIAL: An immunogenic polypeptide conjugate contg. the hepatitis B virus nucleocapsid protein(HBcAg) operatively bonded with the polypeptide immunogen via an amino acid residue side chain.

USE: A vaccine and therapeutic agent for hepatitis B.

PROCESS: For example, the polypeptide corresponding to an HBcAg region is synthesized by a solid phase method of successively bonding the polypeptide to a solid phase carrier according to the amino acid sequence of the polypeptide and the polypeptide is desorbed from the solid carriers, by which the polypeptide is obtd. Next, the polypeptide is air oxidized in a soln. to obtain the synthesized peptide immunogen bonded by a cysteine residue. Further, the

polypeptide is bonded to the HBcAg of the immunogenic carrier activated by m-maleimidebenzoyl-N-hydroxysuccinimide ester, by which the immunogenic polypeptide conjugate is obtd.

LEGAL STATUS

[Date of request for examination]

[Date of sending the examiner's decision of rejection]

[Kind of final disposal of application other than the examiner's decision of rejection or application converted registration]

[Date of final disposal for application]

[Patent number]

[Date of registration]

[Number of appeal against examiner's decision of rejection]

[Date of requesting appeal against examiner's decision of rejection]

[Date of extinction of right]

Copyright (C); 1998,2003 Japan Patent Office